Dr. Tagawa on the Evolution of ADCs in mCRPC
Scott Tagawa, MD, MS, FACP, discusses the evolution of antibody-drug conjugates in metastatic castration-resistant prostate cancer, as well as potential future targets for ADC development in this space.
Dr. Tagawa on the Evolution and Selection of PARP Inhibitors in mCRPC
Scott Tagawa, MD, MS, FACP, discusses the evolution of PARP inhibitor use in metastatic castration-resistant prostate cancer and available PARP inhibitors for molecularly-selected patients in this space.
Dr. Tagawa on the Investigation of 225Ac-J591 and 177Lu-PSMA-I&T in mCRPC
Scott T. Tagawa, MD, MS, FACP, discusses the investigation of 225Ac-J591 and 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer in a phase 1/2 trial.
Optimizing Use of PSMA PET Imaging and PSADT in Prostate Cancer
Shared insight on the respective roles of PSMA-PET imaging and PSA doubling time in the current prostate cancer treatment paradigm.
Overview of Improvements in Prostate Cancer Management
Broad discussion on the evolution of care in prostate cancer from both the therapeutic and imaging standpoints.
Dr. Tagawa on Utilizing Bone-Targeting Radium-223 in Prostate Cancer
Scott T. Tagawa, MD, MS, FACP, discusses the use of radium-223 in prostate cancer.
Genomic Profiling Assays in Metastatic Urothelial Cancer
The significance of using broad genomic profiling tests to help detect promising biomarkers in metastatic urothelial cancer.
Multidisciplinary Care in Metastatic Urothelial Cancer
An overview of the types of health care professionals who may help manage patients with metastatic urothelial cancer throughout their disease course.
Barriers to Molecular Testing in Metastatic Urothelial Cancer
A discussion on molecular testing in the community and recommendations that can address barriers.
Molecular Testing in Metastatic Urothelial Cancer During COVID-19
The impact of the COVID-19 pandemic on rates of molecular testing used by community oncologists who care for patients with urothelial cancer.
Tissue and Liquid Biopsies in Metastatic Urothelial Cancer
A discussion on current prognostic and predictive testing assays used to detect FGFR mutations in patients with metastatic urothelial cancer (mUC).
Testing for FGFR Mutations in Metastatic Urothelial Cancer
Nonmetastatic CRPC: Treatment Selection
An in-depth discussion regarding experience treating nonmetastatic castration-resistant prostate cancer (CRPC) with apalutamide, enzalutamide, and darolutamide, and factors that impact treatment selection.
Advances in Nonmetastatic CRPC
An overview of drug approvals for nonmetastatic castration-resistant prostate cancer (CRPC), and discussion regarding the potential utility of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) to guide treatment decisions.
Oral GnRH Antagonist Therapy for mCSPC
Implications of treating patients with metastatic castration-sensitive prostate cancer with relugolix, an oral GnRH antagonist.
mCSPC: Applying New Data into Clinical Practice
Recommendations for integrating treatment advances in metastatic castration-sensitive prostate cancer into everyday practice.
Triple Therapy Approaches for mCSPC
Potential implications for treating metastatic castration-sensitive prostate cancer with triple therapy based on recently reported data.
ADT Monotherapy in mCSPC
The rationale for treating metastatic castration-sensitive prostate cancer with androgen deprivation therapy as monotherapy as the field advances with newer combination approaches.
Treatment Advances in mCSPC
Dr. Tagawa on the Integration of PSMA-Targeted Agents in Prostate Cancer
Scott Tagawa, MD, MS, FACP, discuss the integration of targeted agents in prostate cancer.
PSMA-Targeted 18F-DCFPyL PET/CT in High-Risk Prostate Cancer
An interpretation of the OSPREY study of 18F-DCFPyL injection in patients with high-risk prostate cancer and implications of its use.
Tissue and Liquid Biopsies in Advanced Prostate Cancer
Dr Scott T. Tagawa comments on the pros and cons of liquid and tissue biopsies used to assess patients with advanced prostate cancer.
Precision Medicine in Advanced Prostate Cancer
A panel of physicians who work in the field of genitourinary oncology comment on the evolving role of precision medicine in advanced prostate cancer.
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma
Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS
2 Clarke Drive Cranbury, NJ 08512